0 59

Cited 0 times in

Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir

DC FieldValueLanguage
dc.contributor.author김승업-
dc.contributor.author이정일-
dc.contributor.author이현웅-
dc.contributor.author임태섭-
dc.date.accessioned2020-12-01T16:57:36Z-
dc.date.available2020-12-01T16:57:36Z-
dc.date.issued2020-10-
dc.identifier.issn1352-0504-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180061-
dc.description.abstractThe risk of developing hepatocellular carcinoma (HCC) after hepatitis B e antigen seroclearance (ESC) remains unclear. We established and validated a new risk prediction model for HCC development after ESC in patients with chronic hepatitis B (CHB) receiving antiviral therapy (AVT). Between 2006 and 2016, 769 patients (training cohort) and 1,061 patients (validation cohort) with CHB who experienced ESC during AVT using entecavir (ETV) or tenofovir disoproxil fumarate (TDF) were recruited. In the multivariate analysis, male sex (hazard ratio [HR] = 2.092; 95% confidence interval [CI] = 1.152-3.800), cirrhosis (HR = 5.141; 95% CI = 2.367-11.167) and fibrosis-4 index (FIB-4) of >3.25 (HR = 2.070; 95% CI = 1.184-3.620) were the independent risk factors for HCC development (all P < .05). Accordingly, a novel HCC-ESCAVT model was developed (1x[sex: male = 1, female = 0] + 3x(cirrhosis = 1, noncirrhosis = 0) + 1x(FIB-4: >3.25 = 1, ≤3.25 = 0). The cumulative risk for HCC development was significantly different among the risk groups based on the HCC-ESCAVT category (0-1, 2-4 and 5 for the low-, intermediate- and high-risk groups, respectively) (overall P < .001, log-rank test). The area under the receiver operating characteristic curve (AUC) for predicting HCC development 3, 5 and 10 years after ESC was 0.791, 0.771 and 0.790, respectively (all P < .05). The predictive value of the HCC-ESCAVT model was similar in the validation cohort (AUC = 0.802, 0.774 and 0.776 at 3, 5 and 10 years, respectively; all P < .05). Hence, we have developed and validated a new HCC-ESCAVT model for HCC development, which includes male sex, cirrhosis and FIB-4 of >3.25 as constituent variables.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF VIRAL HEPATITIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePredictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorTae Seop Lim-
dc.contributor.googleauthorHyun Woong Lee-
dc.contributor.googleauthorJung Il Lee-
dc.contributor.googleauthorIn Hee Kim-
dc.contributor.googleauthorChang Hun Lee-
dc.contributor.googleauthorByoung Kuk Jang-
dc.contributor.googleauthorWoo Jin Chung-
dc.contributor.googleauthorHyung Joon Yim-
dc.contributor.googleauthorSang Jun Suh-
dc.contributor.googleauthorYeon Seok Seo-
dc.contributor.googleauthorHan Ah Lee-
dc.contributor.googleauthorJung Hwan Yu-
dc.contributor.googleauthorJin-Woo Lee-
dc.contributor.googleauthorSang Gyune Kim-
dc.contributor.googleauthorYoung Seok Kim-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorWon Young Tak-
dc.contributor.googleauthorSoon Sun Kim-
dc.contributor.googleauthorJae Youn Cheong-
dc.contributor.googleauthorSoung Won Jeong-
dc.contributor.googleauthorJae Young Jang-
dc.contributor.googleauthorWoo Sun Rou-
dc.contributor.googleauthorByung Seok Lee-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorKorean Transient Elastography Study Group-
dc.identifier.doi10.1111/jvh.13316-
dc.contributor.localIdA00654-
dc.contributor.localIdA03122-
dc.contributor.localIdA03122-
dc.contributor.localIdA03292-
dc.contributor.localIdA03292-
dc.contributor.localIdA03414-
dc.contributor.localIdA03414-
dc.relation.journalcodeJ01928-
dc.identifier.eissn1365-2893-
dc.identifier.pmid32383246-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/jvh.13316-
dc.subject.keywordhepatitis B-
dc.subject.keywordhepatitis B e antigen-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordrisk prediction-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor이정일-
dc.contributor.affiliatedAuthor이정일-
dc.contributor.affiliatedAuthor이현웅-
dc.contributor.affiliatedAuthor이현웅-
dc.contributor.affiliatedAuthor임태섭-
dc.contributor.affiliatedAuthor임태섭-
dc.citation.volume27-
dc.citation.number10-
dc.citation.startPage1052-
dc.citation.endPage1060-
dc.identifier.bibliographicCitationJOURNAL OF VIRAL HEPATITIS, Vol.27(10) : 1052-1060, 2020-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.